October 23, 2015 review Open access Complement, a target for therapy in inflammatory and degenerative diseases Nature Reviews Drug Discovery DOI: 10.1038/nrd4657 Full text (OA) OpenAlex Authors 0 Author list not loaded yet. Cited by 3 stored of 441 Search Sort Most cited Newest Oldest Patent citations Title Any typearticle review book-chapter conference-paper preprint dissertation book dataset other Any fieldAgricultural and Biological Sciences Arts and Humanities Biochemistry, Genetics and Molecular Biology Business, Management and Accounting Chemical Engineering Chemistry Computer Science Decision Sciences Dentistry Earth and Planetary Sciences Economics, Econometrics and Finance Energy Engineering Environmental Science Health Professions Immunology and Microbiology Materials Science Mathematics Medicine Neuroscience Nursing Pharmacology, Toxicology and Pharmaceutics Physics and Astronomy Psychology Social Sciences Veterinary Open access Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial 2022 The Lancet Haematology article Immunology and Microbiology Complement system in diseases Open access 74 citations Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria 2021 New England Journal of Medicine article Immunology and Microbiology Complement system in diseases Open access cited by 1 patent 407 citations Mathematical Modelling of Alternative Pathway of Complement System 2020 Bulletin of Mathematical Biology article Immunology and Microbiology Complement system in diseases Open access 13 citations 3 results References 0